ANGLE Dirección

Dirección controles de criterios 3/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Andrew David Newland

Chief Executive Officer (CEO)

UK£264.0k

Compensación total

Porcentaje del salario del CEO	95.8%
Permanencia del CEO	20.1yrs
Participación del CEO	2.8%
Permanencia media de la dirección	1.3yrs
Promedio de permanencia en la Junta Directiva	8.8yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Andrew David Newland en comparación con los beneficios de ANGLE?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2023	n/a	n/a	-UK£22m
Mar 31 2023	n/a	n/a	-UK£22m
Dec 31 2022	UK£264k	UK£253k	-UK£22m
Sep 30 2022	n/a	n/a	-UK£19m
Jun 30 2022	n/a	n/a	-UK£17m
Mar 31 2022	n/a	n/a	-UK£16m
Dec 31 2021	UK£446k	UK£242k	-UK£15m
Sep 30 2021	n/a	n/a	-UK£15m
Jun 30 2021	n/a	n/a	-UK£16m
Mar 31 2021	n/a	n/a	-UK£14m
Dec 31 2020	UK£392k	UK£240k	-UK£12m
Jun 30 2020	n/a	n/a	-UK£10m
Mar 31 2020	n/a	n/a	-UK£11m
Dec 31 2019	UK£244k	UK£160k	-UK£11m
Oct 31 2019	n/a	n/a	-UK£10m
Jul 31 2019	n/a	n/a	-UK£9m
Apr 30 2019	n/a	n/a	-UK£9m
Jan 31 2019	n/a	n/a	-UK£9m
Oct 31 2018	n/a	n/a	-UK£8m
Jul 31 2018	n/a	n/a	-UK£8m
Apr 30 2018	UK£336k	UK£229k	-UK£8m
Oct 31 2017	n/a	n/a	-UK£7m
Jul 31 2017	n/a	n/a	-UK£7m
Apr 30 2017	UK£231k	UK£227k	-UK£7m

Compensación vs. Mercado: Andrew David($USD331.82K) está por debajo de la media de empresas de tamaño similar en el mercado US ($USD740.57K).

Compensación vs. Ingresos: Andrew Davidha sido coherente con los resultados de la empresa en el último año.

CEO

Andrew David Newland (62 yo)

20.1yrs

Permanencia

UK£264,000

Compensación

Mr. Andrew David William Newland, Meng, ACA founded ANGLE Plc in 1994 and serves as its Group Chief Executive. Mr. Newland founded Provexis, the first ever spin-out of Rowett Institute, Europe’s leading nu...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Andrew David Newland	Founder	no data	UK£264.00k	2.8% £ 1.1m
Ian Griffiths	CFO, Finance Director	6.8yrs	UK£164.00k	0.49% £ 188.7k
Martin Cooke	Director of Operations & Regulatory Affairs	6.3yrs	sin datos	sin datos
Karen Miller	Chief Scientific Officer	1.3yrs	sin datos	sin datos
Andrew Holder	Head of Investor Relations	no data	sin datos	sin datos
Anne-Sophie Pailhes-Jimenez	Head of R&D and Senior Director	less than a year	sin datos	sin datos
Brett Swansiger	Chief Commercial Officer	1.3yrs	sin datos	sin datos
Nick Claxton	Senior Vice President of Commercial Operations	1.3yrs	sin datos	sin datos

1.3yrs

Permanencia media

57yo

Promedio de edad

Equipo directivo experimentado: ANPC.YEl equipo directivo de la empresa no se considera experimentado ( 0.9 años de permanencia media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Andrew David Newland	Founder	20.1yrs	UK£264.00k	2.8% £ 1.1m
Ian Griffiths	CFO, Finance Director	20.1yrs	UK£164.00k	0.49% £ 188.7k
Harold Swerdlow	Member of Scientific Advisory Board	no data	sin datos	sin datos
Juliet Thompson	Non-Executive Director	1.3yrs	sin datos	sin datos
Ashok Venkitaraman	Member of Scientific Advisory Board	no data	sin datos	sin datos
Brian Howlett	Non-Executive & Senior Independent Director	11.3yrs	UK£27.00k	0.0038% £ 1.5k
Jan Groen	Independent Non-Executive Chairman	5.4yrs	UK£27.00k	sin datos
Clive Stanway	Member of Scientific Advisory Board	no data	sin datos	sin datos
Adrian Newland	Member of Scientific Advisory Board	no data	sin datos	sin datos
James Reuben	Member of Scientific Advisory Board	8.8yrs	sin datos	sin datos
Daniel Danila	Member of Scientific Advisory Board	8.8yrs	sin datos	sin datos
Greg Shaw	Member of Scientific Advisory Board	no data	sin datos	sin datos

8.8yrs

Permanencia media

62yo

Promedio de edad

Junta con experiencia: La junta directiva de ANPC.Y se considera experimentada (8.5 años de antigüedad promedio).

ANGLE Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

ANGLE plc Announces Senior Management Appointments

ANGLE plc Announces Board Changes

ANGLE plc Announces Appointment of Joseph (Joe) Eid as Non-Executive Director

ANGLE plc Announces Appointment of Juliet Thompson as Non-Executive Director

ANGLE plc, Annual General Meeting, Jun 29, 2022

Recent updates

Angle plc Announces Use of Parsortix System in Pre-Clinical Model Unlocks Opportunities for Drug Discovery

ANGLE plc Launches Portrait+ CTC Kit At SABCS

ANGLE plc Provides Earnings Guidance for the Year 2023

ANGLE plc Provides Earnings Guidance for the Year 2023

ANGLE plc Announces the Launch of Its Portrait® PD-L1 Test for the Evaluation of PD-L1 Protein Expression on CTCs Following Extensive Development and Optimisation

Angle plc Announces the Launch of Its Portrait™ Flex Ctc Assay

ANGLE plc Announces Senior Management Appointments

ANGLE plc Announces Board Changes

ANGLE plc Announces Appointment of Joseph (Joe) Eid as Non-Executive Director

ANGLE plc to Report Fiscal Year 2022 Results on Jun 02, 2023

ANGLE plc Announces Appointment of Juliet Thompson as Non-Executive Director

ANGLE plc Announces the Publication of Results from A Multi-Centre Clinical Study

Angle plc Announces It Presented Results from A Proof of Concept Study At the International Society of Liquid Biopsy Meeting in Miami, Florida

ANGLE plc Announces Streamlining of Operations to Increase Cash Runway

ANGLE plc Announces Positive Headline Results from Ovarian Study

ANGLE plc Announces Study Using Parsortix in Head and Neck Cancer

ANGLE plc Announces the Publication of Results from A Clinical Study Undertaken in Partnership with the Wilmot Cancer Institute, University of Rochester, NY, US

Angle plc Announces New Study Highlights Use of Parsortix System to Enable Cancer Cell Dna Analysis in Non-Small Cell Lung Cancer

ANGLE plc Announces Ground-Breaking Research by the World-Class Team at the Molecular Oncology Laboratory at the Swiss Federal Institute of Technology Zurich, Switzerland

Angle plc Announces Results of Work Undertaken in Advanced Non-Small Cell Lung Cancer (NSCLC) and Sarcoma Patients

Angle plc Receives FDA Clearance for Parsortix

ANGLE plc, Annual General Meeting, Jun 29, 2022

ANGLE plc to Report Fiscal Year 2021 Results on Apr 28, 2022

Angle Announces Parsortix System Shows Potential for Providing Rapid Information on Patient Response to Therapies Targeting Metastasis

ANGLE plc Announces the Edith Cowan University, Perth, Australia, Has Published Results from A Study in Ovarian Cancer Patients Using the Parsortix® System

ANGLE plc Announces the Publication of Research Undertaken by the World-Class Team At the University of Southern California Norris Cancer Center

ANGLE plc Provides Update on Lab Accreditation and Ovarian Study

ANGLE plc Announces Parsortix System Demonstrates Ability to Isolate CTCS for Downstream Gene Analysis Revealing Multiple Prognostic Biomarkers

Angle plc Announces That the Health Research Institute of Santiago

ANGLE plc Announces Published Results of A New Study Undertaken in Non-Small Cell Lung Cancer

Angle plc Announces Breakthrough Research Supports Potential Use of Parsortix in Prevention of Relapse of Breast Cancer Patients in Remission

Angle's Parsortix System Harvests Intact CTCs for Whole Genomic Sequencing Identifying Multiple Druggable Targets

ANGLE plc Announces Patient Enrolment Completed in Ovarian Cancer Clinical Verification Study

Angle plc Provides Update on Submission for FDA Clearance of the Parsortix System

Angle plc Announces Results of New Study Undertaken in Non-Small Cell Lung Cancer

ANGLE plc Announces Publication of New Data Demonstrating the Performance of its Parsortix® System in a Head-to-Head Comparison with a Antibody-Based CTC System

ANGLE plc Announces FDA Completes its Administrative Review and Accepts ANGLE's FDA Submission for Substantive Review

ANGLE plc Announces Completion of FDA Submission

ANGLE plc Announces Potential Treatment Strategy to Limit Metastasis

ANGLE plc to Report 8 Months Period Ending Dec 31, 2019 Results on Jun 25, 2020

ANGLE plc to Report First Half, 2020 Results on Oct 29, 2020

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad